Value and affordability of CAR T-cell therapy in the United States
Salvatore Fiorenza, David S Ritchie, Scott D Ramsey, Cameron J Turtle, Joshua A Roth
Bone Marrow Transplantation | NATURE PUBLISHING GROUP | Published : 2020
In the United States the increasing number of Food and Drug Administration (FDA)-approved, innovative, and potentially effective commercial cancer therapies pose a significant financial burden on public and private payers. Chimeric antigen receptor (CAR) T cells are prototypical of this challenge. In 2017 and 2018, tisagenlecleucel (Kymriah, Novartis) and axicabtagene ciloleucel (Yescarta, Kite) were approved by the FDA for use after showing groundbreaking results in relapsed/refractory B-cell malignancies. In 2020 and 2021, four further submissions to the FDA are expected for CAR T-cell therapies for indolent and aggressive B-cell malignancies and plasma cell myeloma. Yet, with marketed pri..View full abstract
This study was supported in part by funds from the Fred Hutchinson Cancer Research Center Integrated Immunotherapy Research Center (PI: Roth JA).